研究报告 |
|
|
|
|
Ozanimod(RPC1063)在少突胶质前体细胞分化中的作用和机制 * |
张莹1,2,孔祥熙2,侯琳1,王树坤2,**(),袁增强1,2,**() |
1 青岛大学基础医学院 青岛 266071 2 军事医学研究院军事认知与脑科学研究所 北京 100850 |
|
Role and Mechanism of Ozanimod (RPC1063) in Oligodendrocyte Precursor Cell Differentiation |
ZHANG Ying1,2,KONG Xiang-xi2,HOU Lin1,WANG Shu-kun2,**(),YUAN Zeng-qiang1,2,**() |
1 School of Basic Medicine, Qingdao University, Qingdao 266071, China 2 Institute of Military Cognition and Brain Sciences, Academy of Military Medical Sciences, Beijing 100850, China |
引用本文:
张莹,孔祥熙,侯琳,王树坤,袁增强. Ozanimod(RPC1063)在少突胶质前体细胞分化中的作用和机制 *[J]. 中国生物工程杂志, 2020, 40(6): 10-19.
ZHANG Ying,KONG Xiang-xi,HOU Lin,WANG Shu-kun,YUAN Zeng-qiang. Role and Mechanism of Ozanimod (RPC1063) in Oligodendrocyte Precursor Cell Differentiation. China Biotechnology, 2020, 40(6): 10-19.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.1912021
或
https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I6/10
|
[1] |
Rosenthal J F, Hoffman B M, Tyor W R . CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. J Investig Med, 2020,68(2):321-330.
pmid: 31582425
|
[2] |
Vega-Riquer J M, Mendez-Victoriano G, Morales-Luckie R A , et al. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol, 2019,17(2):129-141.
pmid: 28714395
|
[3] |
Hartley M D, Banerji T, Tagge I J , et al. Myelin repair stimulated by CNS-selective thyroid hormone action. JCI Insight, 2019,4(8):e126329.
|
[4] |
Akaishi T, Nakashima I . Efficiency of antibody therapy in demyelinating diseases. Int Immunol, 2017,29(7):327-335.
|
[5] |
Höftberger R, Lassmann H . Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol, 2017,145:263-283.
|
[6] |
Franklin R J, Ffrench-Constant C . Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci, 2008,9(11):839-855.
pmid: 18931697
|
[7] |
Franco P G, Silvestroff L, Soto E F , et al. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol, 2008,212(2):458-467.
doi: 10.1016/j.expneurol.2008.04.039
pmid: 18572165
|
[8] |
Mi S, Miller R H, Tang W , et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol, 2009,65(3):304-315.
|
[9] |
Brinkmann V . Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther, 2007,115(1):84-105.
|
[10] |
Martin R, Sospedra M . Sphingosine-1 phosphate and central nervous system. Curr Top Microbiol Immunol, 2014,378:149-170.
doi: 10.1007/978-3-319-05879-5_7
pmid: 24728597
|
[11] |
Zhang J, Zhang Z G, Li Y , et al. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis, 2015,76:57-66.
|
[12] |
Khatri B O . Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord, 2016,9(2):130-147.
|
[13] |
Cohen J A, Barkhof F, Comi G , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med, 2010,362(5):402-415.
doi: 10.1056/NEJMoa0907839
pmid: 20089954
|
[14] |
Taylor Meadows K R, Steinberg M W, Clemons B , et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One, 2018,13(4):e0193236.
doi: 10.1371/journal.pone.0193236
pmid: 29608575
|
[15] |
Cohen J A, Arnold D L, Comi G , et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 2016,15(4):373-381.
|
[16] |
Cohen J A, Comi G, Arnold D L , et al. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler, 2019,25(9):1255-1262.
pmid: 30043658
|
[17] |
Cohen J A, Comi G, Selmaj K W , et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol, 2019,18(11):1021-1033.
pmid: 31492652
|
[18] |
Rasche L, Paul F . Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother, 2018,19(18):2073-2086.
|
[19] |
Chaudhry B Z, Cohen J A, Conway D S . Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics, 2017,14(4):859-873.
doi: 10.1007/s13311-017-0565-4
pmid: 28812220
|
[20] |
Wang L, Yang H, Zang C , et al. CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis. Neurobiol Dis, 2020,134:104630.
doi: 10.1016/j.nbd.2019.104630
pmid: 31678404
|
[21] |
Varas R, Ortiz F C . Neuroinflammation in demyelinating diseases: oxidative stress as a modulator of glial cross-talk. Curr Pharm Des, 2019,25(45):4755-4762.
doi: 10.2174/1381612825666191216125725
pmid: 31840603
|
[22] |
Qiu K, He Q, Chen X , et al. Pregnancy-related immune changes and demyelinating diseases of the central nervous system. Front Neurol, 2019,10:1070.
doi: 10.3389/fneur.2019.01070
pmid: 31649614
|
[23] |
Scott F L, Clemons B, Brooks J , et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. British Journal of Pharmacology, 2016,173(11):1778-1792.
|
[24] |
Wong K K . Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov, 2009,4(1):28-35.
doi: 10.2174/157489209787002461
pmid: 19149686
|
[25] |
Sun X, Liu Y, Liu B , et al. Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse. Exp Neurol, 2012,237(2):304-311.
pmid: 22836144
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|